ArticleBMC cancer2026

Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.

Tianwei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.